help me make a well structured table of a drug icotokinra
Searching the Web
icotokinra drug profile mechanism of action indications dosage
Searching PubMed
icotokinra IL-31 receptor antagonist
Reading Web Page
https://www.skintherapyletter.com/psoriasis/icotrokinra-oral…
Searching PubMed
icotrokinra psoriasis clinical trial
I now have comprehensive, high-quality data from the FDA label, Skin Therapy Letter review, and multiple Phase 3 trials. Here is the complete drug table:
Note: The drug you are referring to is icotrokinra (brand name ICOTYDE). "Icotokinra" appears to be a misspelling - all data below refers to the correct drug.
Icotrokinra (ICOTYDE) - Drug Profile
1. Basic Identification
| Parameter | Details |
|---|---|
| Generic Name | Icotrokinra |
| Brand Name | ICOTYDE |
| Drug Class | Interleukin-23 receptor (IL-23R) antagonist; macrocyclic peptide |
| First-in-Class | Yes - first oral IL-23R antagonist |
| Manufacturer | Janssen (Johnson & Johnson) |
| FDA Approval | 2026 (U.S.) |
| Dosage Form | Tablet, 200 mg; film-coated, oval, yellowish orange to yellowish brown; debossed with "200" / "JNJ" |
2. Mechanism of Action
| Parameter | Details |
|---|---|
| Target | Interleukin-23 receptor (IL-23R) |
| Binding | Selectively binds IL-23R with very high affinity (Kd = 7 pM) |
| Effect | Blocks IL-23 (p19/p40 heterodimer) from engaging the IL-23R/IL-12Rβ1 receptor complex on IL-23R+ cells |
| Downstream | Inhibits IL-23-dependent signaling → reduces production of IL-17, IL-22, and other proinflammatory cytokines |
| Pathway targeted | IL-23/Th17 inflammatory axis |
| Selectivity | Does not inhibit CYP450 enzymes or drug transporters; no off-target biologic activity |
3. Indications
| Indication | Population | Notes |
|---|---|---|
| Moderate-to-severe plaque psoriasis | Adults and adolescents ≥12 years, weighing ≥40 kg | Candidates for systemic therapy or phototherapy |
4. Dosage and Administration
| Parameter | Details |
|---|---|
| Recommended dose | 200 mg orally once daily |
| Administration | On an empty stomach with water, upon waking |
| Food restriction | Wait ≥30 minutes before eating after dosing |
| High-fat meal effect | Reduces AUC by 43% and Cmax by 59% - must avoid with food |
| Special populations | No dose adjustment needed for age, weight, sex, race, or mild renal impairment |
| Hepatic impairment | No dose adjustment expected (not hepatically metabolized); severe hepatic impairment not studied |
| Renal impairment | No significant PK change in mild impairment; severe not formally studied |
5. Pharmacokinetics
| Parameter | Details |
|---|---|
| Tmax | Median 2 hours (range: 0.25-8 hours) |
| Cmax (200 mg) | 3.62 ng/mL (SD 1.48) |
| AUCinf (200 mg) | 44.8 ng·h/mL (SD 11.4) |
| Half-life (t½) | ~9-12 hours |
| Steady state | Reached in ~3 days |
| Accumulation | Cmax up to 1.6-fold; AUC up to 1.5-fold with multiple dosing |
| Protein binding | 52% |
| Volume of distribution (Vd) | ~92,800 L (apparent, oral) |
| Metabolism | Not metabolized - unchanged drug is the only plasma species |
| Excretion | Primarily fecal (unchanged); urinary excretion <0.001% |
| GI absorption | Minimal systemic absorption; macrocyclic structure resists GI proteolysis |
| PK linearity | Dose-proportional from 25 mg to 1000 mg |
6. Drug Interactions
| Parameter | Details |
|---|---|
| CYP450 inhibition | Does not inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4 |
| CYP450 induction | Does not induce CYP1A2, 2B6, 3A4 |
| Transporter systems | Not a substrate or inhibitor of P-gp, BCRP, OATP1B1/3, OAT1/3, OCT2, MATE1/2-K, BSEP |
| Overall DDI risk | Negligible - no clinically significant drug-drug interactions identified |
| Caffeine | No clinically significant PK interaction |
7. Contraindications and Precautions
| Category | Details |
|---|---|
| Contraindications | None listed in the FDA label |
| Hypersensitivity | Avoid in patients with known hypersensitivity to icotrokinra or its excipients |
| Pregnancy | Not recommended - no safety data available |
| Pediatric use | Approved for ages ≥12 years (≥40 kg); not approved for <12 years |
| Infections | Use with caution in patients with active infections (class-effect consideration for immune-modulating agents) |
| QTc prolongation | No clinically significant QTc prolongation even at 5x the recommended dose |
| Cardiac electrophysiology | No cardiac safety signal identified |
8. Clinical Efficacy (Key Trial Data)
| Trial | Phase | Design | Primary Endpoint | Key Result |
|---|---|---|---|---|
| FRONTIER-1 (NCT05223868) | 2 | RCT, placebo-controlled, 5 dose arms, 16 weeks | PASI 75 at week 16 | Dose-dependent response; 100 mg OD and BID showed best responses |
| ICONIC-LEAD | 3 | RCT, 24 weeks, adults + adolescents ≥12 yrs | IGA 0/1 and PASI 90 | IGA 0/1: 65% (icotrokinra) vs. 8% (placebo); PASI 90: 50% vs. 4% |
| ICONIC-ADVANCE 1 & 2 (Lancet 2025) | 3 | RCT vs. placebo + active comparator (deucravacitinib) | PASI 75/90, IGA | Superior to placebo; comparable to deucravacitinib benchmark |
| ICONIC high-impact sites (NEJM Evidence 2025) | 3 | RCT, multicenter | Clearance at high-impact sites (scalp, nails, palms) | Significant improvement vs. placebo in difficult-to-treat areas |
9. Safety Profile
| Category | Details |
|---|---|
| Most common AEs | Nasopharyngitis, upper respiratory tract infections (mild) |
| Serious AEs | Uncommon; no new or unexpected safety signals |
| Serious infections | Uncommon |
| Laboratory abnormalities | None identified |
| Dose-dependent toxicity | Not observed |
| Organ-specific toxicity | None identified |
| Overall AE rate vs. comparator | Lower than deucravacitinib; comparable to placebo in controlled phases |
| Safety in adolescents | No new safety signals in ≥12-year-old population |
10. Storage
| Parameter | Details |
|---|---|
| Temperature | Room temperature, 15-25°C |
| Special conditions | No special storage requirements reported |
11. Key Clinical References
| Type | Citation |
|---|---|
| FDA Label | ICOTYDE Prescribing Information, 2026 |
| Phase 3 RCT (NEJM) | Bissonnette R et al. N Engl J Med. 2025 - PMID 41191940 |
| Phase 3 RCT (Lancet) | Gold LS et al. Lancet. 2025 - PMID 40976249 |
| Phase 3 (High-impact sites) | Gooderham M et al. NEJM Evid. 2025 - PMID 41191932 |
| Meta-analysis | Altayf A et al. Int J Dermatol. 2026 - PMID 41846234 |
| Review (Skin Therapy Letter) | Icotrokinra - Skin Therapy Letter |
Summary: Icotrokinra (ICOTYDE) is a first-in-class oral macrocyclic peptide that blocks the IL-23 receptor with picomolar affinity. Approved by the FDA in 2026 for moderate-to-severe plaque psoriasis in patients ≥12 years, it offers biologic-comparable efficacy (PASI 90 in ~50% of patients) with the convenience of once-daily oral dosing, no hepatic metabolism, negligible drug interactions, and a favorable safety profile superior to existing oral agents like deucravacitinib.
This is a shared conversation. Sign in to Orris to start your own chat.